Identifying the effect of vancomycin on health care-associated methicillin-resistant Staphylococcus aureus strains using bacteriological and physiological media.

Delivery of Health Care Humans Methicillin-Resistant Staphylococcus aureus / genetics Microbial Sensitivity Tests Staphylococcal Infections / drug therapy Vancomycin / pharmacology

Journal

GigaScience
ISSN: 2047-217X
Titre abrégé: Gigascience
Pays: United States
ID NLM: 101596872

Informations de publication

Date de publication:
09 01 2021
Historique:
received: 20 10 2020
revised: 24 11 2020
accepted: 03 12 2020
entrez: 9 1 2021
pubmed: 10 1 2021
medline: 26 10 2021
Statut: ppublish

Résumé

The evolving antibiotic-resistant behavior of health care-associated methicillin-resistant Staphylococcus aureus (HA-MRSA) USA100 strains are of major concern. They are resistant to a broad class of antibiotics such as macrolides, aminoglycosides, fluoroquinolones, and many more. The selection of appropriate antibiotic susceptibility examination media is very important. Thus, we use bacteriological (cation-adjusted Mueller-Hinton broth) as well as physiological (R10LB) media to determine the effect of vancomycin on USA100 strains. The study includes the profiling behavior of HA-MRSA USA100 D592 and D712 strains in the presence of vancomycin through various high-throughput assays. The US100 D592 and D712 strains were characterized at sub-inhibitory concentrations through growth curves, RNA sequencing, bacterial cytological profiling, and exo-metabolomics high throughput experiments. The study reveals the vancomycin resistance behavior of HA-MRSA USA100 strains in dual media conditions using wide-ranging experiments.

Sections du résumé

BACKGROUND
The evolving antibiotic-resistant behavior of health care-associated methicillin-resistant Staphylococcus aureus (HA-MRSA) USA100 strains are of major concern. They are resistant to a broad class of antibiotics such as macrolides, aminoglycosides, fluoroquinolones, and many more.
FINDINGS
The selection of appropriate antibiotic susceptibility examination media is very important. Thus, we use bacteriological (cation-adjusted Mueller-Hinton broth) as well as physiological (R10LB) media to determine the effect of vancomycin on USA100 strains. The study includes the profiling behavior of HA-MRSA USA100 D592 and D712 strains in the presence of vancomycin through various high-throughput assays. The US100 D592 and D712 strains were characterized at sub-inhibitory concentrations through growth curves, RNA sequencing, bacterial cytological profiling, and exo-metabolomics high throughput experiments.
CONCLUSIONS
The study reveals the vancomycin resistance behavior of HA-MRSA USA100 strains in dual media conditions using wide-ranging experiments.

Identifiants

DOI: 10.1093/gigascience/giaa156 PMID: 33420779 PMC: PMC7794652
pubmed: 33420779
pii: 6072295
doi: 10.1093/gigascience/giaa156
pmc: PMC7794652
pii:
doi:

Substances chimiques

Vancomycin 6Q205EH1VU

Banques de données

figshare
['10.6084/m9.figshare.12246251', '10.6084/m9.figshare.12246257', '10.6084/m9.figshare.12246248']

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NICHD NIH HHS
ID : P50 HD090259
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI124316
Pays : United States

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press GigaScience.

Références

Biostatistics. 2007 Jan;8(1):118-27
pubmed: 16632515
PLoS Pathog. 2016 Oct 6;12(10):e1005837
pubmed: 27711163
Ann Intern Med. 1982 Sep;97(3):309-17
pubmed: 7114627
Yale J Biol Med. 2017 Jun 23;90(2):269-281
pubmed: 28656013
Anal Cell Pathol. 2003;25(1):1-36
pubmed: 12590175
Clin Infect Dis. 1998 Jul;27(1):10-22
pubmed: 9675443
Cell. 2017 Apr 06;169(2):258-272.e17
pubmed: 28388410
Curr Opin Biotechnol. 2018 Jun;51:130-136
pubmed: 29414439
Proc Natl Acad Sci U S A. 2020 Jul 21;117(29):17228-17239
pubmed: 32616573
Proc Natl Acad Sci U S A. 2013 Oct 1;110(40):16169-74
pubmed: 24046367
Clin Infect Dis. 2011 Jul 15;53(2):158-63
pubmed: 21690622
J Antimicrob Chemother. 2000 Sep;46(3):369-76
pubmed: 10980162
Bioinformatics. 2012 Mar 15;28(6):882-3
pubmed: 22257669
Clin Infect Dis. 2013 Jun;56(12):1779-88
pubmed: 23511300
Antimicrob Agents Chemother. 2011 Sep;55(9):4154-60
pubmed: 21709080
Antibiotics (Basel). 2020 Apr 29;9(5):
pubmed: 32365460
Cell. 2019 May 30;177(6):1649-1661.e9
pubmed: 31080069
Springerplus. 2013 Dec;2(1):133
pubmed: 23565358
Sci Data. 2019 Apr 26;6(1):43
pubmed: 31028276
Nat Commun. 2020 May 22;11(1):2580
pubmed: 32444610
Crit Care. 2017 Aug 14;21(1):211
pubmed: 28807042
Nat Rev Microbiol. 2009 Sep;7(9):629-41
pubmed: 19680247
Nat Methods. 2012 Mar 04;9(4):357-9
pubmed: 22388286
PLoS One. 2014 Apr 22;9(4):e92760
pubmed: 24755631
EBioMedicine. 2016 Jan 18;4:95-103
pubmed: 26981574
Essays Biochem. 2018 Oct 26;62(4):563-574
pubmed: 30315095
Sci Data. 2019 Dec 17;6(1):322
pubmed: 31848353
Nat Commun. 2020 Aug 31;11(1):4365
pubmed: 32868761
Metabolomics. 2015;11(3):603-619
pubmed: 25972769
Genome Biol. 2006;7(10):R100
pubmed: 17076895
J Mol Med (Berl). 2014 Feb;92(2):139-49
pubmed: 24297496

Auteurs

Akanksha Rajput (A)

Department of Bioengineering, University of California, 9500 Gilman Dr, La Jolla, CA 92093, USA.

Saugat Poudel (S)

Department of Bioengineering, University of California, 9500 Gilman Dr, La Jolla, CA 92093, USA.

Hannah Tsunemoto (H)

Division of Biological Sciences, University of California, San Diego, 9500 Gilman Dr, La Jolla, CA 92093, USA.

Michael Meehan (M)

Collaborative Mass Spectrometry Innovation Center, University of California San Diego, 9500 Gilman Dr, La Jolla, CA 92093, USA.
Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, 9500 Gilman Dr, La Jolla, CA 92093, USA.

Richard Szubin (R)

Department of Bioengineering, University of California, 9500 Gilman Dr, La Jolla, CA 92093, USA.

Connor A Olson (CA)

Department of Bioengineering, University of California, 9500 Gilman Dr, La Jolla, CA 92093, USA.

Yara Seif (Y)

Department of Bioengineering, University of California, 9500 Gilman Dr, La Jolla, CA 92093, USA.

Anne Lamsa (A)

Division of Biological Sciences, University of California, San Diego, 9500 Gilman Dr, La Jolla, CA 92093, USA.

Nicholas Dillon (N)

Department of Pediatrics, University of California San Diego, 9500 Gilman Dr, La Jolla, CA 92023, USA.
Collaborative to Halt Antibiotic-Resistant Microbes (CHARM), Department of Pediatrics, University of California San Diego, 9500 Gilman Dr, La Jolla, CA 92093, USA.

Alison Vrbanac (A)

Department of Pediatrics, University of California San Diego, 9500 Gilman Dr, La Jolla, CA 92023, USA.
Collaborative to Halt Antibiotic-Resistant Microbes (CHARM), Department of Pediatrics, University of California San Diego, 9500 Gilman Dr, La Jolla, CA 92093, USA.

Joseph Sugie (J)

Division of Biological Sciences, University of California, San Diego, 9500 Gilman Dr, La Jolla, CA 92093, USA.

Samira Dahesh (S)

Department of Pediatrics, University of California San Diego, 9500 Gilman Dr, La Jolla, CA 92023, USA.
Collaborative to Halt Antibiotic-Resistant Microbes (CHARM), Department of Pediatrics, University of California San Diego, 9500 Gilman Dr, La Jolla, CA 92093, USA.

Jonathan M Monk (JM)

Department of Bioengineering, University of California, 9500 Gilman Dr, La Jolla, CA 92093, USA.

Pieter C Dorrestein (PC)

Collaborative Mass Spectrometry Innovation Center, University of California San Diego, 9500 Gilman Dr, La Jolla, CA 92093, USA.
Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, 9500 Gilman Dr, La Jolla, CA 92093, USA.
Center for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography, University of California San Diego, 9500 Gilman Dr, La Jolla, CA 92093, USA.
Center for Microbiome Innovation, University of California San Diego, 9500 Gilman Dr, La Jolla, CA 92093, USA.

Rob Knight (R)

Department of Bioengineering, University of California, 9500 Gilman Dr, La Jolla, CA 92093, USA.
Department of Pediatrics, University of California San Diego, 9500 Gilman Dr, La Jolla, CA 92023, USA.
Center for Microbiome Innovation, University of California San Diego, 9500 Gilman Dr, La Jolla, CA 92093, USA.
Department of Computer Science and Engineering, University of California San Diego, 9500 Gilman Dr, La Jolla, CA 92093, USA.

Joe Pogliano (J)

Division of Biological Sciences, University of California, San Diego, 9500 Gilman Dr, La Jolla, CA 92093, USA.

Victor Nizet (V)

Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, 9500 Gilman Dr, La Jolla, CA 92093, USA.
Department of Pediatrics, University of California San Diego, 9500 Gilman Dr, La Jolla, CA 92023, USA.
Collaborative to Halt Antibiotic-Resistant Microbes (CHARM), Department of Pediatrics, University of California San Diego, 9500 Gilman Dr, La Jolla, CA 92093, USA.
Center for Microbiome Innovation, University of California San Diego, 9500 Gilman Dr, La Jolla, CA 92093, USA.

Adam M Feist (AM)

Department of Bioengineering, University of California, 9500 Gilman Dr, La Jolla, CA 92093, USA.
Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Kemitorvet, Building 220, 2800 Kongens, Lyngby, Denmark.

Bernhard O Palsson (BO)

Department of Bioengineering, University of California, 9500 Gilman Dr, La Jolla, CA 92093, USA.
Department of Pediatrics, University of California San Diego, 9500 Gilman Dr, La Jolla, CA 92023, USA.
Center for Microbiome Innovation, University of California San Diego, 9500 Gilman Dr, La Jolla, CA 92093, USA.
Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Kemitorvet, Building 220, 2800 Kongens, Lyngby, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Prestations des soins de santé › Identifying the effect of vancomycin on health...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Identifying the effect of vancomycin on health...
questionsmedicales.fr › Bactéries › Bactéries à Gram positif › Cocci à Gram positif › Staphylococcaceae › Staphylococcus › Staphylococcus aureus › Staphylococcus aureus résistant à la méticilline › Identifying the effect of vancomycin on health...
questionsmedicales.fr › Techniques d'investigation › Évaluation préclinique de médicament › Tests de sensibilité microbienne › Identifying the effect of vancomycin on health...
questionsmedicales.fr › Infection › Infections bactériennes et mycoses › Infections bactériennes › Infections bactériennes à Gram positif › Infections à staphylocoques › Identifying the effect of vancomycin on health...
questionsmedicales.fr › Acides aminés, peptides et protéines › Peptides › Glycopeptides › Vancomycine › Identifying the effect of vancomycin on health...